DENMARK —Novo Nordisk has expanded its collaboration with Amalgam Rx, a US-based company to support the commercialization of Dose Check, a digital insulin initiation and titration app.
Dose Check digital insulin initiation and titration app is designed the app to help people with type 2 diabetes using basal insulin.
Amalgam’s prescription-only app offers physicians a selection of clinically validated insulin dosing algorithms that can be tailored to the specific needs of people with Type 2 diabetes.
Dose Check is intended to address the challenges that people with type 2 diabetes may face when starting on basal insulin.
Fear of hypoglycemia, burdensome regimens, and anxiety, according to research, can all delay the initiation of basal insulin, as well as the adjustment and intensification of dosing.
Another study discovered that more than 70% of patients have no recollection of discussing dose titration with their healthcare provider.
Amalgam Rx believes that a mobile app called Dose Check will make it easier for patients to begin using basal insulin.
Novo Nordisk, a leading insulin provider, sees potential in the technology and has expanded its alliance with Amalgam Rx and invested in the company to help Dose Check commercialize.
The two companies partnered to incorporate and integrate connected insulin delivery devices, continuous glucose monitors, and electronic health records. Novo Nordisk also intends to make an equity investment in Amalgam, according to a news release.
The expanded partnership aims to bolster the existing agreement and product suite between Amalgam Rx and Novo Nordisk.
Amalgam Rx’s platform helps alleviate the stresses of starting insulin therapy. The company said those with type 2 diabetes often feel anxiety and confusion.
Additionally, healthcare providers can also find it challenging and time-consuming to decipher incomplete and inaccurate self-management data.
Dose Check allows physicians to choose from clinically-validated basal insulin algorithms and tailor them to patients’ needs.
Patients record their blood glucose levels and the app can suggest an increase in insulin based on their doctor’s recommendation.
Novo Nordisk initially collaborated with Amalgam Rx to commercialize Dose Check, a rebranded version of iSage Rx, in select South American markets.
Last year, Novo Nordisk embarked on a global expansion spanning multiple countries in Europe and Asia after receiving a CE mark for iSage Rx and Dose Check.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
